HR Execs on the Move

Radioisotope Life Sciences

www.rls.bio

 
RLS (Radioisotope Life Sciences), the third-largest nuclear medicine pharmacy network in the United States, owns and operates 31 radiopharmacies across 18 states, offering an extensive portfolio of molecular imaging products. We endeavor to supply the highest quality radiopharmaceuticals in the industry by dispensing 100 percent of injectable unit dose products in clean rooms built to ISO 1644-1 specifications. In support of our commitment to quality, we provide tailored solutions and exceptional service to our more than 1500 customers.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.rls.bio
  • 801 International Parkway Suite 5092
    Lake Mary, FL USA 32746
  • Phone: 813.285.3065

Executives

Name Title Contact Details

Similar Companies

Meadow Lane Pharmacy

Meadow Lane Pharmacy is a Lincoln, NE-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Modus Health

Alvogen

Alvogen is a multinational, privately owned pharmaceuticals company focused on developing, manufacturing and distributing generic, brand, over-the-counter brands (OTC) and biosimilar products. With more than 200 pharmaceutical projects in development and registration, the group`s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of: oncology, cardiology, respiratory, neurology and gastroenterology. Alvogen has commercial operations in over 30 countries with 2,000 employees. North America is Alvogen`s single largest market and other key markets include: South-Korea, Romania, Bulgaria, Hungary, Taiwan, Russia and China.

Laser Pharmceuticals

Laser Pharmceuticals is a Greenville, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Olema

Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. At Olema we leverage the exquisite knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development.